环极素作为肠道微生物群的调节剂:药物应用和对肠道健康的影响
Renata Maria Varut1, Mircea Sorin Ciolofan2, Maria Elena Veronica3
1Research Methodology Department, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Pharmaceutics
|June 27, 2025
概括
环极素 (CDs) 可以积极改变肠道细菌,促进有益的微生物和短链脂肪酸. 这表明CD可以作为药物增强剂和肠道健康的益生菌.
科学领域:
- 制药科学 制药科学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 环极素 (CD) 越来越多地用于制药,以提高药物的溶解性和疗效.
- 肠道微生物群在健康中的作用需要评估诸如CDs之类的辅助物质对微生物群落的影响.
研究的目的:
- 审查环极素对肠道微生物群组成和功能的影响.
- 探索CDs作为制药辅助剂和肠道健康调节剂的潜在双重作用.
主要方法:
- 在PubMed,ScienceDirect和谷歌学者中进行PRISMA指导的文献搜索.
- 对研究循环德克斯-肠道微生物群相互作用的研究进行分析.
主要成果:
- 环极素 (α-, β-, γ-CDs) 调节肠道微生物群,促进有益的细菌 (例如Bifidobacterium,Akkermansia).
- CD补充剂增加了短链脂肪酸 (SCFA) 的产生,支持肠道平衡.
- CDs显示在降低脂质和降低血糖控制方面具有潜力,而不会影响胰岛素分泌.
结论:
- 环极素作为药物辅助剂具有有望对肠道微生物群产生潜在的益生菌作用.
- 需要使用元遗传学和代谢学方法进行进一步的研究,以了解CD-微生物群机制并优化应用.
相关概念视频
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
325
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
325
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
205
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
205
Drugs for Treatment of Constipation-Predominant IBS
351
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
351
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
269
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
269
Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
272
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
272


